Welcome to our dedicated page for Aemetis SEC filings (Ticker: AMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aemetis, Inc. filings document the renewable fuels company's operating results, governance, capital structure, and material agreements tied to its renewable natural gas, ethanol, and biodiesel businesses.
Recent Form 8-K reports furnish quarterly and annual earnings releases, Regulation FD materials, changes in the independent registered public accounting firm, amendments to the Delaware certificate of incorporation, stockholder voting results, financing-related agreements at Aemetis Biogas, and related-party guarantee-fee and executive compensation arrangements. Proxy materials cover board matters, executive pay, equity awards, annual meeting matters, and voting procedures for AMTX common stock listed on the Nasdaq Global Market.
Aemetis, Inc. has approved the engagement of KPMG LLP as its independent registered public accounting firm starting with the quarter ending March 31, 2026 and the fiscal year ending December 31, 2026, subject to an engagement letter. The Audit Committee also dismissed RSM US LLP as auditor effective after completion of the December 31, 2025 audit and related non-audit services, ending a relationship that began in 2012. RSM’s reports on the 2024 and 2025 financial statements contained no adverse or qualified opinions, but each included an explanatory paragraph about Aemetis’ ability to continue as a going concern. The company reports no disagreements with RSM and notes previously disclosed material weaknesses in internal control over financial reporting as of December 31, 2024, which were discussed with RSM and about which KPMG may inquire.
Aemetis, Inc. filed its annual report describing a diversified renewable fuels business spanning California ethanol and dairy renewable natural gas (RNG) plus India biodiesel. The company reported a 2025 net loss of $77.0 million, narrowing from $87.5 million in 2024, and an accumulated deficit of $639.9 million as of December 31, 2025.
Keyes ethanol volumes declined to 57 million gallons sold in 2025 from 61 million, while RNG gas sold rose to 399 thousand MMBtu from 302 thousand, and LCFS credits sold increased to 83 thousand. India biodiesel volumes fell sharply to 21 thousand metric tons from 74 thousand. Aemetis highlights large capital projects in sustainable aviation fuel, renewable diesel, and carbon capture, but also discloses heavy leverage, including about $247.9 million owed under Third Eye Capital notes due on demand and $46.2 million of 2025 interest expense.
Aemetis, Inc. reported 2025 results showing strong growth in its dairy renewable natural gas platform but continued overall losses and a weaker top line. Full-year revenues were $197.6 million plus $10.4 million of production tax credits, down from $267.6 million of revenue in 2024. Net loss narrowed to $77.0 million from $87.5 million, helped by cost reductions and tax credit sales.
The dairy RNG segment produced about 405,000 MMBtu in 2025 and increased fourth-quarter production by 61% year over year, generating $9.6 million of gross profit versus $5.4 million in 2024. The California ethanol plant delivered $158.3 million of 2025 revenue and credits, while India biodiesel revenue fell to $29.7 million amid tender delays.
Fourth-quarter 2025 revenue and production tax credits totaled $53.7 million, up from $47.0 million a year earlier, and gross profit improved to $7.7 million from a $2.0 million gross loss. Cash increased to $4.9 million at year-end 2025, but Aemetis carried a stockholders’ deficit of $306.8 million and current liabilities of $371.3 million against total assets of $259.8 million.
Aemetis, Inc. amended its Certificate of Incorporation to increase authorized capital stock to 205,000,000 shares, including a rise in authorized common stock from 80,000,000 to 140,000,000 shares, following stockholder approval at a special meeting.
Stockholders did not approve a reduction in authorized preferred stock from 65,000,000 to 5,000,000 shares, but did approve a discretionary adjournment proposal. Aemetis also updated the official description of its capital stock and filed a legal opinion covering the legality of up to $210,000,000 of common stock that may be sold from time to time under its existing at‑the‑market offering program.
Aemetis, Inc. reported that its subsidiary Aemetis Biogas LLC entered into an Eleventh Waiver and Amendment to its Series A Preferred Unit Purchase Agreement with Protair-X Technologies Inc. and Third Eye Capital Corporation. The amendment extends the deadline to redeem all outstanding Series A Preferred Units from December 31, 2025 to April 30, 2026 and sets the aggregate redemption price at $114.7 million, which reflects prior payments and a $2 million fee for this amendment. If the units are not redeemed by the new date, Aemetis Biogas LLC would instead enter into a credit agreement with Protair-X and Third Eye Capital, effective May 1, 2026, maturing May 1, 2027, with interest at the greater of 16.0% or the prime rate plus 10.0%, guaranteed by Aemetis, Inc. and several subsidiaries and secured by their assets.
Aemetis, Inc. director Simon Timothy Alan received a grant of 12,000 shares of Common Stock on January 22, 2026 at $1.54 per share. The award was made under the Aemetis Amended and Restated 2019 Stock Plan as compensation for his service on the Board of Directors.
After this equity grant, he beneficially owns 52,632 shares of Aemetis Common Stock in direct form.
Aemetis director John R. Block received a grant of 12,000 shares of Aemetis common stock on 01/22/2026 at a price of $1.54 per share. The shares were granted under the Aemetis, Inc. Amended and Restated 2019 Stock Plan as compensation for his service on the Board of Directors.
After this award, he beneficially owns 46,330 shares of Aemetis common stock in direct form.
Aemetis, Inc. director Barton Francis P reported receiving a grant of 18,000 shares of Common Stock on January 22, 2026. The award was priced at $1.54 per share and was issued as compensation for service on the Board of Directors under the Aemetis, Inc. Amended and Restated 2019 Stock Plan.
Following this equity grant, Barton Francis P beneficially owns 226,518 shares of Aemetis Common Stock in direct ownership.
Aemetis, Inc. director Lydia I. Beebe reported receiving a grant of common stock as board compensation. On 01/22/2026, she was awarded 14,500 shares of Aemetis common stock at $1.54 per share under the company’s Amended and Restated 2019 Stock Plan. Following this grant, she beneficially owns 214,286 common shares, held directly. The transaction reflects routine equity-based compensation for service on the Board of Directors.
Aemetis, Inc. director Naomi Louise Boness reported a stock grant received for board service. On 01/22/2026 she acquired 12,000 shares of Aemetis common stock at $1.54 per share under the Aemetis, Inc. Amended and Restated 2019 Stock Plan, as compensation for serving on the Board of Directors. Following this grant, she beneficially owned 64,643 common shares held directly.